Table of Content
1. Executive Summary
1.1. Global Sales Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Overview
2.1. Coverage / Taxonomy
2.2. Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Trends
3.1. Key Trends
3.2. Development/Innovation Trends
4. Value-Added Insights
4.1. Product Assessment
4.1.1. Product Adoption Analysis
4.1.2. Recent Product Launches and Innovations
4.1.3. Product Matrix Analysis
4.2. Pipeline Assessment
4.2.1. By Drug Class
4.2.2. Comprehensive Assessment by Phases
4.2.3. Emerging Novel Trends
4.2.4. Late-stage Pipeline Drugs Assessment
4.3. Disease Epidemiology
4.3.1. Prevalence Population
4.3.2. Diagnosed Prevalence Cases
4.3.3. Severity-Specific Cases
4.4. Reimbursement Landscape
4.5. Regulatory Scenario
4.5.1. Regulatory Frameworks in Europe
4.6. PESTEL Analysis – by Region
4.7. Porters Analysis
4.8. Supply Chain Analysis
5. Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure
5.1.2. Pharmaceutical Spending Outlook
5.1.3. Research & Development Funding By Region
5.1.4. R&D Funding By County
5.1.5. Expenditure on Retail Pharmaceuticals Per Capita
5.1.6. Overall Generic Drugs Sales Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Historical Growth of Key Players
5.2.2. Consolidation Activities
5.2.3. Increasing Regulatory Approvals
5.2.4. Rising Prevalence of Cancer and Cardiovascular Diseases
5.2.5. Rising Demand for Super Generics for Pain Management
5.2.6. Cost Effectiveness of Super Generic
5.2.7. Increasing Research and Development
5.3. Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Europe Demand (in Value or Size in US$ billion) Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Value (US$ billion) Analysis, 2018 to 2022
6.2. Current and Future Value (US$ billion) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Size (US$ billion) Analysis by Drug Class, 2018 to 2022
7.3. Current and Future Size (US$ billion) Analysis and Forecast by Drug Class, 2023 to 2033
7.3.1. Antihistamines
7.3.2. Antimicrotubule Agents
7.3.3. Aryl Acetic Acid Derivatives
7.3.4. Atypical Antipsychotics
7.3.5. Anti-Diabetic
7.3.6. Anti-Obesity Drugs
7.3.7. Calcium Channel Blockers
7.3.8. Corticosteroids
7.3.9. Fibric Acid Agents
7.3.10. GABA Analogs
7.3.11. Opioid Analgesics
7.3.12. Proton Pump Inhibitors
7.3.13. Retinoids
7.3.14. Others
7.4. Attractiveness Analysis by Drug Class
8. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
8.1. Introduction / Key Findings
8.2. Historical Size (US$ billion) By Route of Administration, 2018 to 2022
8.3. Current and Future Size (US$ billion) Analysis and Forecast by Route of Administration, 2023 to 2033
8.3.1. Oral
8.3.2. Topical
8.3.3. Parenteral
8.3.4. Others
8.4. Attractiveness Analysis by Route of Administration
9. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
9.1. Introduction / Key Findings
9.2. Historical Size (US$ billion) By Indication, 2018 to 2022
9.3. Current and Future Size (US$ billion) Analysis and Forecast by Indication, 2023 to 2033
9.3.1. Oncology
9.3.2. Cardiology
9.3.3. Diabetics
9.3.4. Neurology
9.3.4.1. Migraine
9.3.4.2. Epilepsy
9.3.4.3. Alzheimer
9.3.4.4. Pain Management
9.3.5. Gastroenterology
9.3.6. Dermatology
9.3.7. Analgesics & Anti-inflammatory
9.3.8. Weight Management
9.3.9. Ophthalmology
9.3.10. Others
9.4. Attractiveness Analysis by Indication
10. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Size (US$ billion) By Distribution Channel, 2018 to 2022
10.3. Current and Future Size (US$ billion) Analysis and Forecast by Distribution Channel, 2023 to 2033
10.3.1. Hospital
10.3.2. Specialty Clinics
10.3.3. Retail Pharmacies
10.3.4. Drug Stores
10.3.5. Online Pharmacies/ Mail Order Pharmacies
10.4. Attractiveness Analysis by Distribution Channel
11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
11.1. Introduction / Key Findings
11.2. Historical Size (US$ billion) Trend Analysis by Region, 2018 to 2022
11.3. Current and Future Size (US$ billion) Analysis and Forecast by Region, 2022–2032
11.3.1. Western Europe
11.3.1.1. United Kingdom
11.3.1.2. Germany
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain
11.3.1.6. BENELUX
11.3.1.7. Nordics
11.3.2. Eastern Europe
11.3.2.1. Poland
11.3.2.2. Hungary
11.3.2.3. Romania
11.3.2.4. Russia
11.3.2.5. Checz Republic
11.3.3. Rest of Europe
11.4. Attractiveness Analysis by States
12. United Kingdom Analysis 2018 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
12.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
12.3.1. By States
12.3.1.1. England
12.3.1.2. Wales
12.3.1.3. Northern Ireland
12.3.1.4. Scotland
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Indication
12.3.5. By Distribution Channel
12.4. Attractiveness Analysis
12.4.1. By States
12.4.2. By Drug Class
12.4.3. By Route of Administration
12.4.4. By Indication
12.4.5. By Distribution Channel
12.5. Drivers and Restraints - Impact Analysis
12.6. State-Level Analysis & Forecast
12.6.1. England Analysis
12.6.1.1. Introduction
12.6.1.2. Analysis and Forecast by Taxonomy
12.6.1.2.1. Drug Class
12.6.1.2.2. By Route of Administration
12.6.1.2.3. By Indication
12.6.1.2.4. By Distribution Channel
12.6.2. Wales Analysis
12.6.2.1. Introduction
12.6.2.2. Analysis and Forecast by Taxonomy
12.6.2.2.1. Drug Class
12.6.2.2.2. By Route of Administration
12.6.2.2.3. By Indication
12.6.2.2.4. By Distribution Channel
12.6.3. Northern Ireland Analysis
12.6.3.1. Introduction
12.6.3.2. Analysis and Forecast by Taxonomy
12.6.3.2.1. Drug Class
12.6.3.2.2. By Route of Administration
12.6.3.2.3. By Indication
12.6.3.2.4. By Distribution Channel
12.6.4. Scotland Analysis
12.6.4.1. Introduction
12.6.4.2. Analysis and Forecast by Taxonomy
12.6.4.2.1. Drug Class
12.6.4.2.2. By Route of Administration
12.6.4.2.3. By Indication
12.6.4.2.4. By Distribution Channel
13. Germany Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
13.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
13.3.1. By States
13.3.1.1. Baden-Württemberg
13.3.1.2. Bavaria
13.3.1.3. Lower Saxony
13.3.1.4. Hesse
13.3.1.5. Rest of Germany
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Indication
13.3.5. By Distribution Channel
13.4. Attractiveness Analysis
13.4.1. By States
13.4.2. By Drug Class
13.4.3. By Route of Administration
13.4.4. By Indication
13.4.5. By Distribution Channel
13.5. Drivers and Restraints - Impact Analysis
13.6. States Level Analysis & Forecast
13.6.1. Baden-Württemberg Analysis
13.6.1.1. Introduction
13.6.1.2. Analysis and Forecast by Taxonomy
13.6.1.2.1. Drug Class
13.6.1.2.2. By Route of Administration
13.6.1.2.3. By Indication
13.6.1.2.4. By Distribution Channel
13.6.2. Bavaria Analysis
13.6.2.1. Introduction
13.6.2.2. Analysis and Forecast by Taxonomy
13.6.2.2.1. Drug Class
13.6.2.2.2. By Route of Administration
13.6.2.2.3. By Indication
13.6.2.2.4. By Distribution Channel
13.6.3. Argentina Analysis
13.6.3.1. Introduction
13.6.3.2. Analysis and Forecast by Taxonomy
13.6.3.2.1. Drug Class
13.6.3.2.2. By Route of Administration
13.6.3.2.3. By Indication
13.6.3.2.4. By Distribution Channel
13.6.4. Lower Saxony Analysis
13.6.4.1. Introduction
13.6.4.2. Analysis and Forecast by Taxonomy
13.6.4.2.1. Drug Class
13.6.4.2.2. By Route of Administration
13.6.4.2.3. By Indication
13.6.4.2.4. By Distribution Channel
13.6.5. Hesse Analysis
13.6.5.1. Introduction
13.6.5.2. Analysis and Forecast by Taxonomy
13.6.5.2.1. Drug Class
13.6.5.2.2. By Route of Administration
13.6.5.2.3. By Indication
13.6.5.2.4. By Distribution Channel
14. Spain Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
14.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
14.3.1. By States
14.3.1.1. Madrid
14.3.1.2. Barcelona
14.3.1.3. Valencia
14.3.1.4. Seville
14.3.1.5. Rest of Spain
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Indication
14.3.5. By Distribution Channel
14.4. Attractiveness Analysis
14.4.1. By States
14.4.2. By Drug Class
14.4.3. By Route of Administration
14.4.4. By Indication
14.4.5. By Distribution Channel
14.5. Drivers and Restraints - Impact Analysis
14.6. States Level Analysis & Forecast
14.6.1. Madrid Analysis
14.6.1.1. Introduction
14.6.1.2. Analysis and Forecast by Taxonomy
14.6.1.2.1. Drug Class
14.6.1.2.2. By Route of Administration
14.6.1.2.3. By Indication
14.6.1.2.4. By Distribution Channel
14.6.2. Barcelona Analysis
14.6.2.1. Introduction
14.6.2.2. Analysis and Forecast by Taxonomy
14.6.2.2.1. Drug Class
14.6.2.2.2. By Route of Administration
14.6.2.2.3. By Indication
14.6.2.2.4. By Distribution Channel
14.6.3. Valencia Analysis
14.6.3.1. Introduction
14.6.3.2. Analysis and Forecast by Taxonomy
14.6.3.2.1. Drug Class
14.6.3.2.2. By Route of Administration
14.6.3.2.3. By Indication
14.6.3.2.4. By Distribution Channel
14.6.4. Seville Analysis
14.6.4.1. Introduction
14.6.4.2. Analysis and Forecast by Taxonomy
14.6.4.2.1. Drug Class
14.6.4.2.2. By Route of Administration
14.6.4.2.3. By Indication
14.6.4.2.4. By Distribution Channel
15. Italy Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
15.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
15.3.1. By States
15.3.1.1. Rome
15.3.1.2. Abruzzo
15.3.1.3. Basilicata
15.3.1.4. Calabria
15.3.1.5. Rest of Italy
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Indication
15.3.5. By Distribution Channel
15.4. Attractiveness Analysis
15.4.1. By States
15.4.2. By Drug Class
15.4.3. By Route of Administration
15.4.4. By Indication
15.4.5. By Distribution Channel
15.5. Drivers and Restraints - Impact Analysis
15.6. States Level Analysis & Forecast
15.6.1. Rome Analysis
15.6.1.1. Introduction
15.6.1.2. Analysis and Forecast by Taxonomy
15.6.1.2.1. Drug Class
15.6.1.2.2. By Route of Administration
15.6.1.2.3. By Indication
15.6.1.2.4. By Distribution Channel
15.6.2. Abruzzo Analysis
15.6.2.1. Introduction
15.6.2.2. Analysis and Forecast by Taxonomy
15.6.2.2.1. Drug Class
15.6.2.2.2. By Route of Administration
15.6.2.2.3. By Indication
15.6.2.2.4. By Distribution Channel
15.6.3. Basilicata Analysis
15.6.3.1. Introduction
15.6.3.2. Analysis and Forecast by Taxonomy
15.6.3.2.1. Drug Class
15.6.3.2.2. By Route of Administration
15.6.3.2.3. By Indication
15.6.3.2.4. By Distribution Channel
15.6.4. Calabria Analysis
15.6.4.1. Introduction
15.6.4.2. Analysis and Forecast by Taxonomy
15.6.4.2.1. Drug Class
15.6.4.2.2. By Route of Administration
15.6.4.2.3. By Indication
15.6.4.2.4. By Distribution Channel
16. France Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
16.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
16.3.1. By States
16.3.1.1. Auvergne - Rhône-Alpes
16.3.1.2. Bretagne (Brittany)
16.3.1.3. Bourgogne - Franche-Comté
16.3.1.4. Ile de France (Paris)
16.3.1.5. Rest of France
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By Indication
16.3.5. By Distribution Channel
16.4. Attractiveness Analysis
16.4.1. By States
16.4.2. By Drug Class
16.4.3. By Route of Administration
16.4.4. By Indication
16.4.5. By Distribution Channel
16.5. Drivers and Restraints - Impact Analysis
16.6. States Level Analysis & Forecast
16.6.1. Auvergne - Rhône-Alpes Analysis
16.6.1.1. Introduction
16.6.1.2. Analysis and Forecast by Taxonomy
16.6.1.2.1. Drug Class
16.6.1.2.2. By Route of Administration
16.6.1.2.3. By Indication
16.6.1.2.4. By Distribution Channel
16.6.2. Bretagne (Brittany) Analysis
16.6.2.1. Introduction
16.6.2.2. Analysis and Forecast by Taxonomy
16.6.2.2.1. Drug Class
16.6.2.2.2. By Route of Administration
16.6.2.2.3. By Indication
16.6.2.2.4. By Distribution Channel
16.6.3. Bourgogne - Franche-Comté Analysis
16.6.3.1. Introduction
16.6.3.2. Analysis and Forecast by Taxonomy
16.6.3.2.1. Drug Class
16.6.3.2.2. By Route of Administration
16.6.3.2.3. By Indication
16.6.3.2.4. By Distribution Channel
16.6.4. Ile de France (Paris) Analysis
16.6.4.1. Introduction
16.6.4.2. Analysis and Forecast by Taxonomy
16.6.4.2.1. Drug Class
16.6.4.2.2. By Route of Administration
16.6.4.2.3. By Indication
16.6.4.2.4. By Distribution Channel
17. BENELUX Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
17.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Belgium
17.3.1.2. Netherlands
17.3.1.3. Luxembourg
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Indication
17.3.5. By Distribution Channel
17.4. Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Route of Administration
17.4.4. By Indication
17.4.5. By Distribution Channel
17.5. Drivers and Restraints - Impact Analysis
17.6. Country Level Analysis & Forecast
17.6.1. Belgium Analysis
17.6.1.1. Introduction
17.6.1.2. Analysis and Forecast by Taxonomy
17.6.1.2.1. Drug Class
17.6.1.2.2. By Route of Administration
17.6.1.2.3. By Indication
17.6.1.2.4. By Distribution Channel
17.6.2. Netherland Analysis
17.6.2.1. Introduction
17.6.2.2. Analysis and Forecast by Taxonomy
17.6.2.2.1. Drug Class
17.6.2.2.2. By Route of Administration
17.6.2.2.3. By Indication
17.6.2.2.4. By Distribution Channel
17.6.3. Luxemburg Analysis
17.6.3.1. Introduction
17.6.3.2. Analysis and Forecast by Taxonomy
17.6.3.2.1. Drug Class
17.6.3.2.2. By Route of Administration
17.6.3.2.3. By Indication
17.6.3.2.4. By Distribution Channel
18. Nordics Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
18.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Denmark
18.3.1.2. Norway
18.3.1.3. Sweden
18.3.1.4. Finland
18.3.1.5. Rest of Nordics
18.3.2. By Drug Class
18.3.3. By Route of Administration
18.3.4. By Indication
18.3.5. By Distribution Channel
18.4. Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Class
18.4.3. By Route of Administration
18.4.4. By Indication
18.4.5. By Distribution Channel
18.5. Drivers and Restraints - Impact Analysis
18.6. Country Level Analysis & Forecast
18.6.1. Denmark Analysis
18.6.1.1. Introduction
18.6.1.2. Analysis and Forecast by Taxonomy
18.6.1.2.1. Drug Class
18.6.1.2.2. By Route of Administration
18.6.1.2.3. By Indication
18.6.1.2.4. By Distribution Channel
18.6.2. Norway Analysis
18.6.2.1. Introduction
18.6.2.2. Analysis and Forecast by Taxonomy
18.6.2.2.1. Drug Class
18.6.2.2.2. By Route of Administration
18.6.2.2.3. By Indication
18.6.2.2.4. By Distribution Channel
18.6.3. Sweden Analysis
18.6.3.1. Introduction
18.6.3.2. Analysis and Forecast by Taxonomy
18.6.3.2.1. Drug Class
18.6.3.2.2. By Route of Administration
18.6.3.2.3. By Indication
18.6.3.2.4. By Distribution Channel
18.6.4. Finland Analysis
18.6.4.1. Introduction
18.6.4.2. Analysis and Forecast by Taxonomy
18.6.4.2.1. Drug Class
18.6.4.2.2. By Route of Administration
18.6.4.2.3. By Indication
18.6.4.2.4. By Distribution Channel
19. Poland Analysis 2018 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
19.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
19.3.1. By Drug Class
19.3.2. By Route of Administration
19.3.3. By Indication
19.3.4. By Distribution Channel
19.4. Attractiveness Analysis
19.4.1. By Drug Class
19.4.2. By Route of Administration
19.4.3. By Indication
19.4.4. By Distribution Channel
19.5. Drivers and Restraints - Impact Analysis
20. Hungary Analysis 2018 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
20.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
20.3.1. By Drug Class
20.3.2. By Route of Administration
20.3.3. By Indication
20.3.4. By Distribution Channel
20.4. Attractiveness Analysis
20.4.1. By Drug Class
20.4.2. By Route of Administration
20.4.3. By Indication
20.4.4. By Distribution Channel
20.5. Drivers and Restraints - Impact Analysis
21. Romania Analysis 2018 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
21.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
21.3.1. By Drug Class
21.3.2. By Route of Administration
21.3.3. By Indication
21.3.4. By Distribution Channel
21.4. Attractiveness Analysis
21.4.1. By Drug Class
21.4.2. By Route of Administration
21.4.3. By Indication
21.4.4. By Distribution Channel
21.5. Drivers and Restraints - Impact Analysis
22. Checz Republic Analysis 2018 to 2022 and Forecast 2023 to 2033
22.1. Introduction
22.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
22.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
22.3.1. By Drug Class
22.3.2. By Route of Administration
22.3.3. By Indication
22.3.4. By Distribution Channel
22.4. Attractiveness Analysis
22.4.1. By Drug Class
22.4.2. By Route of Administration
22.4.3. By Indication
22.4.4. By Distribution Channel
22.5. Drivers and Restraints - Impact Analysis
23. Russia Analysis 2018 to 2022 and Forecast 2023 to 2033
23.1. Introduction
23.2. Historical Size (US$ billion) Analysis by Taxonomy, 2018 to 2022
23.3. Current and Future Size (US$ billion) Analysis and Forecast by Taxonomy, 2023 to 2033
23.3.1. By Drug Class
23.3.2. By Route of Administration
23.3.3. By Indication
23.3.4. By Distribution Channel
23.4. Attractiveness Analysis
23.4.1. By Drug Class
23.4.2. By Route of Administration
23.4.3. By Indication
23.4.4. By Distribution Channel
23.5. Drivers and Restraints - Impact Analysis
24. Structure Analysis
24.1. Analysis by Tier of Companies
24.2. Share Analysis of Top Players (%)
24.3. Presence Analysis
24.3.1. Regional footprint of Players
24.3.2. Platform Type foot print by Players
24.3.3. Channel Foot Print by Players
25. Competition Analysis
25.1. Competition Dashboard
25.2. Competition Benchmarking
25.3. Competition Deep Dive
25.3.1. Novartis AG
25.3.1.1. Overview
25.3.1.2. Drug Class Portfolio
25.3.1.3. Key Financials
25.3.1.4. SWOT Analysis
25.3.1.5. Key Developments
25.3.1.6. Sales Footprint
25.3.1.7. Strategy Overview
25.3.1.7.1. Business Strategy
25.3.1.7.2. Drug Class Strategy
25.3.1.7.3. Channel Strategy
25.3.2. AbbVie
25.3.2.1. Overview
25.3.2.2. Drug Class Portfolio
25.3.2.3. Key Financials
25.3.2.4. SWOT Analysis
25.3.2.5. Key Developments
25.3.2.6. Sales Footprint
25.3.2.7. Strategy Overview
25.3.3. Sun Pharmaceutical Industries Ltd.
25.3.3.1. Overview
25.3.3.2. Drug Class Portfolio
25.3.3.3. Key Financials
25.3.3.4. SWOT Analysis
25.3.3.5. Key Developments
25.3.3.6. Sales Footprint
25.3.3.7. Strategy Overview
25.3.4. Endo International
25.3.4.1. Overview
25.3.4.2. Drug Class Portfolio
25.3.4.3. Key Financials
25.3.4.4. SWOT Analysis
25.3.4.5. Key Developments
25.3.4.6. Sales Footprint
25.3.4.7. Strategy Overview
25.3.5. Viatris Inc.
25.3.5.1. Overview
25.3.5.2. Drug Class Portfolio
25.3.5.3. Key Financials
25.3.5.4. SWOT Analysis
25.3.5.5. Key Developments
25.3.5.6. Sales Footprint
25.3.5.7. Strategy Overview
25.3.6. Dr. Reddy's Laboratories Ltd.
25.3.6.1. Overview
25.3.6.2. Drug Class Portfolio
25.3.6.3. Key Financials
25.3.6.4. SWOT Analysis
25.3.6.5. Key Developments
25.3.6.6. Sales Footprint
25.3.6.7. Strategy Overview
25.3.7. Innovida Pharmaceutique
25.3.7.1. Overview
25.3.7.2. Drug Class Portfolio
25.3.7.3. Key Financials
25.3.7.4. SWOT Analysis
25.3.7.5. Key Developments
25.3.7.6. Sales Footprint
25.3.7.7. Strategy Overview
25.3.8. SERB Specialty Pharmaceuticals
25.3.8.1. Overview
25.3.8.2. Drug Class Portfolio
25.3.8.3. Key Financials
25.3.8.4. SWOT Analysis
25.3.8.5. Key Developments
25.3.8.6. Sales Footprint
25.3.8.7. Strategy Overview
25.3.9. Eagle Pharma
25.3.9.1. Overview
25.3.9.2. Drug Class Portfolio
25.3.9.3. Key Financials
25.3.9.4. SWOT Analysis
25.3.9.5. Key Developments
25.3.9.6. Sales Footprint
25.3.9.7. Strategy Overview
26. Assumptions and Acronyms Used
27. Research Methodology
List of Tables
Table 01: Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Drug Class
Table 02: Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Route of Administration
Table 03: Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 04: Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 05: Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 06: Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 07: Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Country
Table 08: Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Country
Table 09: Generic Size Value Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By State
Table 10: United Kingdom Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 11: United Kingdom Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 12: United Kingdom Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 13: United Kingdom Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 14: United Kingdom Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 15: Germany Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By State
Table 16: Germany Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 17: Germany Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 18: Germany Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 19: Germany Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 20: Germany Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 21: Spain Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By State
Table 22: Spain Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 23: Spain Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 24: Spain Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 25: Spain Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 26: Spain Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 27: Italy Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By State
Table 28: Italy Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 29: Italy Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 30: Italy Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 31: Italy Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 32: Italy Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 33: France Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By State
Table 34: France Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 35: France Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 36: France Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 37: France Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 38: France Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 39: BENELUX Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By State
Table 40: BENELUX Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 41: BENELUX Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 42: BENELUX Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 43: BENELUX Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 44: BENELUX Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 45: Nordics Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By State
Table 46: Nordics Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 47: Nordics Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 48: Nordics Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 49: Nordics Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 50: Nordics Size Value (US$ billion) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 51: Poland Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Drug Class
Table 52: Poland Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Route of Administration
Table 53: Poland Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 54: Poland Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 55: Poland Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 56: Hungary Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Drug Class
Table 57: Hungary Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Route of Administration
Table 58: Hungary Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 59: Hungary Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 60: Hungary Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 61: Romania Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Drug Class
Table 62: Romania Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Route of Administration
Table 63: Romania Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 64: Romania Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 65: Romania Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 66: Russia Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Drug Class
Table 67: Russia Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Route of Administration
Table 68: Russia Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 69: Russia Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 70: Russia Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 71: Czech Republic Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Drug Class
Table 72: Czech Republic Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Route of Administration
Table 73: Czech Republic Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 74: Czech Republic Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 75: Czech Republic Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 76: Rest of Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Drug Class
Table 77: Rest of Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Route of Administration
Table 78: Rest of Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 79: Rest of Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Indication
Table 80: Rest of Size Value (US$ billion) Analysis 2018 and 2022 and Forecast 2023 to 2033, By Distribution Channel
List of Charts
Figure 01: Split by Drug Class, 2023 (E)
Figure 02: Split by Route of Administration, 2023 (E)
Figure 03: Split by Indication, 2023 (E)
Figure 04: Split by Distribution Channel, 2023 (E)
Figure 05: Split by Region, 2023 (E)
Figure 06: Value Analysis (US$ billion), 2018 and 2022
Figure 07: Value Forecast (US$ billion), 2023 to 2033
Figure 08: Absolute $ Opportunity, 2022 to 2033
Figure 09: Analysis by Drug Class 2022 and 2033
Figure 10: Y-o-Y Growth Projections by Drug Class, 2023 to 2033
Figure 11: Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 12: Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 13: Y-o-Y Growth (%) By Route of Administration, 2023 to 2033
Figure 14: Attractiveness Analysis By Application, 2023 to 2033
Figure 15: Share Analysis (%) By Indication, 2023 and 2033
Figure 16: Y-o-Y Growth (%) By Indication, 2023 to 2033
Figure 17: Attractiveness Analysis By Indication, 2023 to 2033
Figure 18: Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 19: Y-o-Y Growth (%) By Distribution Channel, 2023 to 2033
Figure 20: Attractiveness Analysis By Distribution Channel, 2023 to 2033
Figure 21: Share Analysis (%) By Country, 2023 and 2033
Figure 22: Y-o-Y Growth (%) By Country, 2023 to 2033
Figure 23: Attractiveness Analysis By Country, 2023 to 2033
Figure 24: United Kingdom Split by Drug Class, 2023 (E)
Figure 25: United Kingdom Split by Route of Administration, 2023 (E)
Figure 26: United Kingdom Split by Indication, 2023 (E)
Figure 27: United Kingdom Split by Distribution Channel, 2023 (E)
Figure 28: United Kingdom Split by State, 2023 (E)
Figure 29: United Kingdom Value Analysis (US$ billion), 2018 to 2022
Figure 30: United Kingdom Value Forecast (US$ billion), 2023 to 2033
Figure 31: United Kingdom Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 32: United Kingdom Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 33: United Kingdom Attractiveness Analysis by Indication, 2023 to 2033
Figure 34: United Kingdom Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 35: United Kingdom Attractiveness Analysis by State, 2023 to 2033
Figure 36: England Share Analysis (%) by Drug Class 2022 and 2033
Figure 37: England Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 38: England Share Analysis (%) By Indication, 2023 and 2033
Figure 39: England Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 40: Wales Share Analysis (%) by Drug Class 2022 and 2033
Figure 41: Wales Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 42: Wales Share Analysis (%) By Indication, 2023 and 2033
Figure 43: Wales Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 44: Northern Ireland Share Analysis (%) by Drug Class 2022 and 2033
Figure 45: Northern Ireland Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 46: Northern Ireland Share Analysis (%) By Indication, 2023 and 2033
Figure 47: Northern Ireland Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 48: Scotland Share Analysis (%) by Drug Class 2022 and 2033
Figure 49: Scotland Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 50: Scotland Share Analysis (%) By Indication, 2023 and 2033
Figure 51: Scotland Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 52: Germany Split by Drug Class, 2023 (E)
Figure 53: Germany Split by Route of Administration, 2023 (E)
Figure 54: Germany Split by Indication, 2023 (E)
Figure 55: Germany Split by Distribution Channel, 2023 (E)
Figure 56: Germany Split by State, 2023 (E)
Figure 57: Germany Value Analysis (US$ billion), 2018 to 2022
Figure 58: Germany Value Forecast (US$ billion), 2023 to 2033
Figure 59: Germany Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 60: Germany Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 61: Germany Attractiveness Analysis by Indication, 2023 to 2033
Figure 62: Germany Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 63: Germany Attractiveness Analysis by State, 2023 to 2033
Figure 64: Baden-Württemberg Share Analysis (%) by Drug Class 2022 and 2033
Figure 65: Baden-Württemberg Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 66: Baden-Württemberg Share Analysis (%) By Indication, 2023 and 2033
Figure 67: Baden-Württemberg Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 68: Bavaria Share Analysis (%) by Drug Class 2022 and 2033
Figure 69: Bavaria Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 70: Bavaria Share Analysis (%) By Indication, 2023 and 2033
Figure 71: Bavaria Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 72: Lower Saxony Share Analysis (%) by Drug Class 2022 and 2033
Figure 73: Lower Saxony Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 74: Lower Saxony Share Analysis (%) By Indication, 2023 and 2033
Figure 75: Lower Saxony Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 76: Hesse Share Analysis (%) by Drug Class 2022 and 2033
Figure 77: Hesse Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 78: Hesse Share Analysis (%) By Indication, 2023 and 2033
Figure 79: Hesse Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 80: Spain Split by Drug Class, 2023 (E)
Figure 81: Spain Split by Route of Administration, 2023 (E)
Figure 82: Spain Split by Indication, 2023 (E)
Figure 83: Spain Split by Distribution Channel, 2023 (E)
Figure 84: Spain Split by State, 2023 (E)
Figure 85: Spain Value Analysis (US$ billion), 2018 to 2022
Figure 86: Spain Value Forecast (US$ billion), 2023 to 2033
Figure 87: Spain Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 88: Spain Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 89: Spain Attractiveness Analysis by Indication, 2023 to 2033
Figure 90: Spain Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 91: Spain Attractiveness Analysis by State, 2023 to 2033
Figure 92: Madrid Share Analysis (%) by Drug Class 2022 and 2033
Figure 93: Madrid Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 94: Madrid Share Analysis (%) By Indication, 2023 and 2033
Figure 95: Madrid Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 96: Barcelona Share Analysis (%) by Drug Class 2022 and 2033
Figure 97: Barcelona Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 98: Barcelona Share Analysis (%) By Indication, 2023 and 2033
Figure 99: Barcelona Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 100: Valencia Share Analysis (%) by Drug Class 2022 and 2033
Figure 101: Valencia Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 102: Valencia Share Analysis (%) By Indication, 2023 and 2033
Figure 103: Valencia Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 104: Seville Share Analysis (%) by Drug Class 2022 and 2033
Figure 105: Seville Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 106: Seville Share Analysis (%) By Indication, 2023 and 2033
Figure 107: Seville Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 108: Italy Split by Drug Class, 2023 (E)
Figure 109: Italy Split by Route of Administration, 2023 (E)
Figure 110: Italy Split by Indication, 2023 (E)
Figure 111: Italy Split by Distribution Channel, 2023 (E)
Figure 112: Italy Split by State, 2023 (E)
Figure 113: Italy Value Analysis (US$ billion), 2018 to 2022
Figure 114: Italy Value Forecast (US$ billion), 2023 to 2033
Figure 115: Italy Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 116: Italy Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 117: Italy Attractiveness Analysis by Indication, 2023 to 2033
Figure 118: Italy Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 119: Italy Attractiveness Analysis by State, 2023 to 2033
Figure 120: Rome Share Analysis (%) by Drug Class 2022 and 2033
Figure 121: Rome Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 122: Rome Share Analysis (%) By Indication, 2023 and 2033
Figure 123: Rome Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 124: Abruzzo Share Analysis (%) by Drug Class 2022 and 2033
Figure 125: Abruzzo Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 126: Abruzzo Share Analysis (%) By Indication, 2023 and 2033
Figure 127: Abruzzo Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 128: Basilicata Share Analysis (%) by Drug Class 2022 and 2033
Figure 129: Basilicata Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 130: Basilicata Share Analysis (%) By Indication, 2023 and 2033
Figure 131: Basilicata Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 132: Calabria Share Analysis (%) by Drug Class 2022 and 2033
Figure 133: Calabria Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 134: Calabria Share Analysis (%) By Indication, 2023 and 2033
Figure 135: Calabria Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 136: France Split by Drug Class, 2023 (E)
Figure 137: France Split by Route of Administration, 2023 (E)
Figure 138: France Split by Indication, 2023 (E)
Figure 139: France Split by Distribution Channel, 2023 (E)
Figure 140: France Split by State, 2023 (E)
Figure 141: France Value Analysis (US$ billion), 2018 to 2022
Figure 142: France Value Forecast (US$ billion), 2023 to 2033
Figure 143: France Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 144: France Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 145: France Attractiveness Analysis by Indication, 2023 to 2033
Figure 146: France Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 147: France Attractiveness Analysis by State, 2023 to 2033
Figure 148: Auvergne - Rhône-Alpes Share Analysis (%) by Drug Class 2022 and 2033
Figure 149: Auvergne - Rhône-Alpes Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 150: Auvergne - Rhône-Alpes Share Analysis (%) By Indication, 2023 and 2033
Figure 151: Auvergne - Rhône-Alpes Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 152: Bretagne (Brittany) Share Analysis (%) by Drug Class 2022 and 2033
Figure 153: Bretagne (Brittany) Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 154: Bretagne (Brittany) Share Analysis (%) By Indication, 2023 and 2033
Figure 155: Bretagne (Brittany) Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 156: Bourgogne - Franche-Comté Share Analysis (%) by Drug Class 2022 and 2033
Figure 157: Bourgogne - Franche-Comté Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 158: Bourgogne - Franche-Comté Share Analysis (%) By Indication, 2023 and 2033
Figure 159: Bourgogne - Franche-Comté Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 160: Ile de France (Paris) Share Analysis (%) by Drug Class 2022 and 2033
Figure 161: Ile de France (Paris) Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 162: Ile de France (Paris) Share Analysis (%) By Indication, 2023 and 2033
Figure 163: Ile de France (Paris) Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 164: BENELUX Split by Drug Class, 2023 (E)
Figure 165: BENELUX Split by Route of Administration, 2023 (E)
Figure 166: BENELUX Split by Indication, 2023 (E)
Figure 167: BENELUX Split by Distribution Channel, 2023 (E)
Figure 168: BENELUX Split by State, 2023 (E)
Figure 169: BENELUX Value Analysis (US$ billion), 2018 to 2022
Figure 170: BENELUX Value Forecast (US$ billion), 2023 to 2033
Figure 171: BENELUX Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 172: BENELUX Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 173: BENELUX Attractiveness Analysis by Indication, 2023 to 2033
Figure 174: BENELUX Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 175: BENELUX Attractiveness Analysis by State, 2023 to 2033
Figure 176: Belgium Share Analysis (%) by Drug Class 2022 and 2033
Figure 177: Belgium Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 178: Belgium Share Analysis (%) By Indication, 2023 and 2033
Figure 179: Belgium Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 180: Netherlands Share Analysis (%) by Drug Class 2022 and 2033
Figure 181: Netherlands Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 182: Netherlands Share Analysis (%) By Indication, 2023 and 2033
Figure 183: Netherlands Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 184: Luxembourg Share Analysis (%) by Drug Class 2022 and 2033
Figure 185: Luxembourg Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 186: Luxembourg Share Analysis (%) By Indication, 2023 and 2033
Figure 187: Luxembourg Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 188: Nordics Split by Drug Class, 2023 (E)
Figure 189: Nordics Split by Route of Administration, 2023 (E)
Figure 190: Nordics Split by Indication, 2023 (E)
Figure 191: Nordics Split by Distribution Channel, 2023 (E)
Figure 192: Nordics Split by State, 2023 (E)
Figure 193: Nordics Value Analysis (US$ billion), 2018 to 2022
Figure 194: Nordics Value Forecast (US$ billion), 2023 to 2033
Figure 195: Nordics Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 196: Nordics Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 197: Nordics Attractiveness Analysis by Indication, 2023 to 2033
Figure 198: Nordics Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 199: Nordics Attractiveness Analysis by State, 2023 to 2033
Figure 200: Denmark Share Analysis (%) by Drug Class 2022 and 2033
Figure 201: Denmark Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 202: Denmark Share Analysis (%) By Indication, 2023 and 2033
Figure 203: Denmark Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 204: Norway Share Analysis (%) by Drug Class 2022 and 2033
Figure 205: Norway Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 206: Norway Share Analysis (%) By Indication, 2023 and 2033
Figure 207: Norway Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 208: Sweden Share Analysis (%) by Drug Class 2022 and 2033
Figure 209: Sweden Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 210: Sweden Share Analysis (%) By Indication, 2023 and 2033
Figure 211: Sweden Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 212: Finland Share Analysis (%) by Drug Class 2022 and 2033
Figure 213: Finland Share Analysis (%) By Route of Administration, 2022 and 2033
Figure 214: Finland Share Analysis (%) By Indication, 2023 and 2033
Figure 215: Finland Share Analysis (%) By Distribution Channel, 2023 and 2033
Figure 216: Poland Split by Drug Class, 2023 (E)
Figure 217: Poland Split by Route of Administration, 2023 (E)
Figure 218: Poland Split by Indication, 2023 (E)
Figure 219: Poland Split by Distribution Channel, 2023 (E)
Figure 220: Poland Value Analysis (US$ billion), 2018 and 2022
Figure 221: Poland Value Forecast (US$ billion), 2023 to 2033
Figure 222: Poland Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 223: Poland Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 224: Poland Attractiveness Analysis by Indication, 2023 to 2033
Figure 225: Poland Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 226: Hungary Split by Drug Class, 2023 (E)
Figure 227: Hungary Split by Route of Administration, 2023 (E)
Figure 228: Hungary Split by Indication, 2023 (E)
Figure 229: Hungary Split by Distribution Channel, 2023 (E)
Figure 230: Hungary Value Analysis (US$ billion), 2018 and 2022
Figure 231: Hungary Value Forecast (US$ billion), 2023 to 2033
Figure 232: Hungary Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 233: Hungary Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 234: Hungary Attractiveness Analysis by Indication, 2023 to 2033
Figure 235: Hungary Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 236: Romania Split by Drug Class, 2023 (E)
Figure 237: Romania Split by Route of Administration, 2023 (E)
Figure 238: Romania Split by Indication, 2023 (E)
Figure 239: Romania Split by Distribution Channel, 2023 (E)
Figure 240: Romania Value Analysis (US$ billion), 2018 and 2022
Figure 241: Romania Value Forecast (US$ billion), 2023 to 2033
Figure 242: Romania Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 243: Romania Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 244: Romania Attractiveness Analysis by Indication, 2023 to 2033
Figure 245: Romania Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 246: Russia Split by Drug Class, 2023 (E)
Figure 247: Russia Split by Route of Administration, 2023 (E)
Figure 248: Russia Split by Indication, 2023 (E)
Figure 249: Russia Split by Distribution Channel, 2023 (E)
Figure 250: Russia Value Analysis (US$ billion), 2018 and 2022
Figure 251: Russia Value Forecast (US$ billion), 2023 to 2033
Figure 252: Russia Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 253: Russia Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 254: Russia Attractiveness Analysis by Indication, 2023 to 2033
Figure 255: Russia Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 256: Czech Republic Split by Drug Class, 2023 (E)
Figure 257: Czech Republic Split by Route of Administration, 2023 (E)
Figure 258: Czech Republic Split by Indication, 2023 (E)
Figure 259: Czech Republic Split by Distribution Channel, 2023 (E)
Figure 260: Czech Republic Value Analysis (US$ billion), 2018 and 2022
Figure 261: Czech Republic Value Forecast (US$ billion), 2023 to 2033
Figure 262: Czech Republic Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 263: Czech Republic Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 264: Czech Republic Attractiveness Analysis by Indication, 2023 to 2033
Figure 265: Czech Republic Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 266: Rest of Split by Drug Class, 2023 (E)
Figure 267: Rest of Split by Route of Administration, 2023 (E)
Figure 268: Rest of Split by Indication, 2023 (E)
Figure 269: Rest of Split by Distribution Channel, 2023 (E)
Figure 270: Rest of Value Analysis (US$ billion), 2018 and 2022
Figure 271: Rest of Value Forecast (US$ billion), 2023 to 2033
Figure 272: Rest of Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 273: Rest of Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 274: Rest of Attractiveness Analysis by Indication, 2023 to 2033
Figure 275: Rest of Attractiveness Analysis by Distribution Channel, 2023 to 2033
